Please assess the completion status of the following clinical trial:

Trial Title: Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Twenty lifetime nonsmokers moderate or severe asthmatics; FEV1≥50 of predicted on the screening day~Exclusion Criteria:~Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women; Cardiovascular disease and/or use of cardiovascular medication; Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance; Acute respiratory infection and or acute exacerbation of asthma within four weeks prior to the study; Use of systemic glucocorticosteroids within 4 weeks prior to the study; Daily ICS dose (fluticasone or budesonide) \> 500ug; Diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- budesonide 360ug (Type: EXPERIMENTAL): asthmatic subject received different doses of inhaled budesonide in random other
- budesonide 720ug (Type: EXPERIMENTAL): asthmatic subject received different doses of inhaled budesonide in random other
- budesonide 1440ug (Type: EXPERIMENTAL): asthmatic subject received different doses of inhaled budesonide in random other
- placebo (Type: PLACEBO_COMPARATOR): asthmatic subject received inhaled placebo
- Budesonide720ug 4 times (Type: EXPERIMENTAL): asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).